Share this page on LinkedIn
Share This Page on Google+
Share This Page on Twitter
tell someone about this page print this page
You are here: Contents > 2018 > Volume 27 Number 1 January 2018 > AORTIC VALVE DISEASE > Evolution of Veterans Affairs Transcatheter Aortic Valve Replacement Program: The First 100 Patients

Evolution of Veterans Affairs Transcatheter Aortic Valve Replacement Program: The First 100 Patients

Joseph Yang1, Jeffrey M. Zimmet1, Vimala M. Ponna2, Frank Ma2, Curtis J. Wozniak2, Liang Ge2,3, Kendrick A. Shunk1, Elaine E. Tseng2

1Division of Cardiology, Department of Medicine, University of California San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA
2Division of Cardiothoracic Surgery, Department of Surgery, University of California San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA
3Electronic correspondence: liang.ge@gmail.com

Background and aim of the study: Transcatheter aortic valve replacement (TAVR) is a widely established alternative to surgery in intermediate- and high-risk patients. TAVR program development within the Veterans Affairs (VA) system has been previously described. However, national TAVR registries do not capture VA outcomes data, and few data have been reported regarding TAVR outcomes at lower-volume federal institutions. The study aim was to demonstrate the evolution of a successful VA TAVR program.

Methods: A retrospective analysis was performed of the first 100 TAVR patients at San Francisco VA Medical Center. Mortality and major complications were evaluated.

Results: Between 25th November 2013 and 31st August 2016, a total of 100 TAVR procedures was performed at the authors’ institution. The mean patient age was 79.7 ± 8.7 years. Patients underwent TAVR via percutaneous-transfemoral (n = 90), surgical cutdown-transfemoral (n = 8), or transapical (n = 2) approaches. The valve systems employed were Edwards SAPIEN (n = 16), SAPIEN XT (n = 31), SAPIEN 3 (n = 23), and Medtronic CoreValve


(n = 16) and CoreValve Evolut R (n = 14). The overall device success was 96%. TAVR-in-TAVR was required in the remaining 4% of patients, and was successful. All-cause procedural mortality was 1%. Complications included tamponade (1%), stroke (2%), temporary hemodialysis (1%), vascular injuries requiring intervention (4%), and permanent pacemaker implantation (14%). There were no conversions to surgical aortic valve replacement. Twenty-two (22%) patients had mild, two (2%) had moderate, and none (0%) had severe paravalvular leakage. The post-procedure aortic valve gradient by echocardiography was 8.6 ± 4.5 mmHg. Follow up was 100% complete and survival was 99%, 93%, and 89% at one, six, and 12 months, respectively.

Conclusions: Successful outcomes were demonstrated for a VA TAVR program that compared favorably with benchmarks established by the National Transcatheter Valve Therapies Registry. These results provide a necessary transparency of TAVR outcomes at a federal institution.

The Journal of Heart Valve Disease 2018;27:24-31


Evolution of Veterans Affairs Transcatheter Aortic Valve Replacement Program: The First 100 Patients

Click the above hyperlink to view the article, right click (Ctrl click on a Mac) to open in a new browser window or tab.

Purchase this Article

Please click the button below to purchase this article. Single article purchases are provided at $50.00 per article. Upon clicking the button below, single article user account subscription details are requested and, upon successful payment, a single article user account is created. Single articles are availble in your account for seven days after purchase.